Genentech, Inc.

Facet Biotech Corporation

New York University

Genetech, Inc.

Pdl Biopharma, Inc.

Abbott Biotherapeutics Corp.

Ingrid W Caras

Vinay Bhaskar

Daniel E Afar

John William Winslow

David Powers

Vanitha Ramakrishnan

Debbie Law

Richard Murray

Agustin De La Calle

David W Martin, Jr

Victor N Nussenzweig

Michael A Davitz

Victor Nussenzweig

David W Martin

Michael Davitz

The invention relates to the identification and generation of antibodies that bind to TMEFF2 proteins which are involved in cancer. Further, the invention provides for the use of these antibodies in the treatment of cancer.

Antibodies against cancer antigen TMEFF2 and uses thereof

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.

AL-1 neurotrophic factor treatments

The present invention provides nucleic acids encoding AL-2 protein, host cells and vectors containing these nucleic acids, and methods for their use to produce AL-2 protein by recombinant DNA methods.

AL-2 neurotrophic factor nucleic acid

Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.

Decay accelerating factor (DAF) and nucleic acid encoding it

The present invention provides methods of enhancing cognitive function in mammals by administering intracerebrally a homo-multimeric immunoadhesin molecule that contains the extracellular domain of AL-1, also known as ephrin-A5.

Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin

Methods of using an AL-1 neurotrophic factor immunoadhesin

AL-1 neurotrophic factor antibodies

This application relates to nucleic acids encoding decay accelerating factor (hereinafter abbreviated as DAF), as well as vectors and cells which comprise such nucleic acids. Additionally, nucleic acids which encode variants of DAF, such as insertion, deletion or substitution variants, are described. This application also relates to the preparation of DAF in recombinant cell culture. In particular, it is concerned with the large scale manufacture of DAF suitable for pharmaceutical or diagnostic use.

Decay accelerating factor (DAF) and nucleic acids encoding it

Provided are nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders. The present invention provides methods to preferentially detect or amplify AL-1 nucleic acid in a sample using AL-1 nucleotide sequence probes.

Methods for detecting nucleic acids encoding AL--1 neurotrophic factor

Methods and compositions for the attachment of proteins to liposomes

Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.

Growing community of inventors

San Francisco, CA, United States of America

Ingrid W Caras